FDA Adverse Event Injury Summary report: N

EUFLEXXA

MDR report key: 16439023 · Received February 24, 2023

Report

Report Number
0002244564-2021-00023
Event Type
Injury
Date Received
February 24, 2023
Report Date
February 24, 2023
Manufacturer
BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.
Product Code
MOZ
Adverse Event
Yes
Report Source
Distributor report
Reporter Location
US
Reporter Occupation
003

Narratives

Description of Event or Problem · 0

ACID REFLUX [GASTROOESOPHAGEAL REFLUX DISEASE]. COPD [CHRONIC OBSTRUCTIVE PULMONARY DISEASE]. CASE NARRATIVE: CASE (B)(4) IS A SERIOUS SPONTANEOUS CASE RECEIVED FROM A NON HEALTH PROFESSIONAL VIA REGULATORY AUTHORITY IN UNITED STATES. THIS REPORT CONCERNS A PATIENT (NO IDENTIFIERS REPORTED) WHO EXPERIENCED ACID REFLUX AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) DURING TREATMENT WITH INTRA-ARTICULAR EUFLEXXA (SODIUM HYALURONATE) SOLUTION FOR INJECTION 10 MG, UNKNOWN DOSE AND FREQUENCY FOR AN UNKNOWN INDICATION FROM AN UNKNOWN START DATE TO AN UNKNOWN STOP DATE. THE NON HEALTH CARE PROFESSIONAL REPORTED THAT THE PATIENT BEING HOSPITALIZED ABOUT A MONTH AGO (UNKNOWN DATE IN (B)(6) 2021) DUE TO HAVING ACID REFLUX AND A MODERATE CASE OF COPD. THE PATIENT ALSO HAD A PACEMAKER IMPLANTED ON AN UNKNOWN DATE ON (B)(6) 2020. ACTION TAKEN WITH EUFLEXXA WAS UNKNOWN. AT THE TIME OF THIS REPORT, THE OUTCOME OF ACID REFLUX WAS UNKNOWN, THE OUTCOME OF COPD WAS UNKNOWN. THE PATIENT'S MED HIST/PROCEDURE WAS SIGNIFICANT FOR PACEMAKER IMPLANTED (FROM (B)(6) 2020). THE FOLLOWING CONCOMITANT MEDICATIONS WERE REPORTED: PANTOPRAZOLE (FROM AN UNKNOWN START DATE TO AN UNKNOWN STOP DATE), ANORO ELLIPTA (FROM AN UNKNOWN START DATE TO AN UNKNOWN STOP DATE), BENAZEPRIL (FROM AN UNKNOWN START DATE TO AN UNKNOWN STOP DATE). ALL EVENTS IN THE CASE WERE REPORTED AS SERIOUS. AT THE TIME OF REPORTING THE CASE OUTCOME WAS UNKNOWN. OVERALL LISTEDNESS (CORE LABEL) IS UNLISTED. REPORTER CAUSALITY: RELATED. COMPANY CAUSALITY: NOT RELATED. OTHER CASE NUMBERS: INTERNAL # OTHERS = MW5101078. SENDER COMMENT: DUE TO CLINICAL INTERPRETATION IN ALIGNMENT WITH KNOWN SAFETY PROFILE, COMPANY CAUSALITY IS CONSIDERED NOT RELATED TO EUFLEXXA FOR THE 'ACID REFLUX' AND THE 'MODERATE CASE OF COPD' EVENTS AS THERE IS NO CLINICAL EVIDENCE FOR THIS. FURTHERMORE, ADMINISTRATION DATES WERE NOT REPORTED, MAKING DIFFICULT TO ESTABLISH A TEMPORAL RELATIONSHIP. THIS AE OCCURRED IN UNITED STATES AND CONCERNS THE MEDICAL DEVICE EUFLEXXA. PLEASE REPORT TO YOUR LOCAL HEALTH AUTHORITY IF REQUIRED BY LOCAL LAW. THIS AE IS NOT REPORTABLE IN EU BECAUSE IT DOES NOT MEET THE DEFINITION OF A MEDICAL DEVICE INCIDENT ACCORDING TO THE REQUIREMENTS OF THE MEDICAL DEVICE DIRECTIVE/ BECAUSE IT DID NOT OCCUR IN A EU + EFTA COUNTRY AND DID NOT RESULT IN A CORRECTIVE ACTION BY THE MANUFACTURER. NO CORRECTIVE ACTION WAS DONE BY THE MANUFACTURER OR REQUESTED BY REGULATORS.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
388159 EUFLEXXA 1%  SODIUM HYALURONATE MOZ BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.

Patients

Seq Age Sex Outcome Treatment
1 Unknown Hospitalization ANORO ELLIPTA (UMECLIDINIUM BROMIDE, VILANTEROL TR| BENAZEPRIL (BENAZEPRIL),| PANTOPRAZOLE (PANTOPRAZOLE),